CANbridge Life Sciences of Beijing Raises $10 Million in Series A Funding

CANbridge Life Sciences, a Beijing biopharma startup, raised $10 million in a Series A round that it will use for new business opportunities and to advance its drug portfolio. The company in-licenses China rights to drug candidates from western drug companies. Investors in the round were Qiming Venture Partners and TF Capital, a VC fund begun by China CRO Tigermed that includes other healthcare companies. More details.... Share this with colleagues: // //